公开(公告)号：EP4141017A1

公开(公告)日：2023-03-01

申请号：EP21792412.5

申请日：2021-04-23

申请人： The University of Tokyo ,  Savid Therapeutics Inc. ,  Tohoku University

发明人： KANAI, Motomu ,  YAMATSUGU, Kenzo ,  TATSUMI, Toshifumi ,  KODAMA, Tatsuhiko ,  SUGIYAMA, Akira ,  TSUKAGOSHI, Masanobu ,  TOKUYAMA, Hidetoshi ,  SAKATA, Juri

IPC分类号： C07K5/04 ,  A61K38/05 ,  A61K47/62 ,  A61K47/68 ,  A61P35/00 ,  C07K7/04 ,  C07K19/00

摘要： It is an object of the present invention to provide a conjugate of a duocarmycin derivative and a biotin-modified dimer, which is useful for pretargeting methods. According to the present invention, a compound represented by the following formula (1) or formula (2) is provided:


wherein R 1 and R 2 each independently represent a hydrogen atom, a lower alkyl group, or a lower alkoxycarbonyl group; one of R 3 , R 4 , and R 5 represents -O-L 7 -(Xaa) m -L 6 -N 3 , and the remaining two each independently represent a hydrogen atom, a lower alkyl group, or a lower alkoxycarbonyl group; X represents a reactive group; L 6 and L 7 each independently represent a divalent linking group; Xaa represents an amino acid residue; m represents an integer of 2 to 10; and Me represents a methyl group.

公开(公告)号：EP4382609A1

公开(公告)日：2024-06-12

申请号：EP22849576.8

申请日：2022-07-28

申请人： The University of Tokyo ,  Savid Therapeutics Inc.

发明人： TANAKA, Toshiya ,  YAMASHITA, Takefumi ,  KODAMA, Tatsuhiko ,  KANAI, Motomu ,  YAMATSUGU, Kenzo ,  TATSUMI, Toshifumi ,  TAKAHASHI, Kazuki ,  SUGIYAMA, Akira ,  TSUKAGOSHI, Masanobu ,  CHANSLER, Michael ,  NAKAI, Masanori

IPC分类号： C12N15/62 ,  A61K31/409 ,  A61K38/16 ,  A61K47/66 ,  A61K49/00 ,  A61P35/00 ,  C07K14/195 ,  C07K16/30 ,  C07K19/00 ,  C12P21/02

CPC分类号： A61K31/409 ,  A61K38/16 ,  A61K47/66 ,  A61K49/00 ,  A61P35/00 ,  C07K14/195 ,  C07K16/30 ,  C07K19/00 ,  C12N15/62 ,  C12P21/02

摘要： It is an object of the present invention to provide a fusion protein of a molecule that recognizes cancer cells or the like and a mutant streptavidin, wherein the fusion protein is for use in the treatment or diagnosis of a cancer. According to the present invention, provided is A fusion protein, wherein an antigen-binding molecule having a molecular weight of 20,000 or less is bound, via a linker sequence, to the N-terminal side and/or C-terminal side of mutant streptavidin which comprises an amino acid sequence having the following mutations (1) to (6) with respect to the amino acid sequence of a core streptavidin as shown in SEQ ID NO: 17 provided that the C-terminal amino acid sequence consisting of Pro-Ser-Ala-Ala-Ser may be partially or entirely deleted, and has a decreased immunogenicity as compared with that of a wild-type streptavidin:
(1) a mutation in which the tyrosine residue at position 10 is substituted with serine or threonine;
(2) a mutation in which the tyrosine residue at position 71 is substituted with alanine or serine;
(3) a mutation in which the arginine residue at position 72 is substituted with lysine;
(4) a mutation in which the glutamic acid residue at position 89 is substituted with aspartic acid;
(5) a mutation in which the arginine residue at position 91 is substituted with lysine; and
(6) a mutation in which the glutamic acid residue at position 104 is substituted with glutamine or asparagine.